Elevance Health, Inc. is a health insurance company that provides managed care plans and healthcare services across the United States. The company operates through four reportable segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. Its core go-to-market brands include Anthem Blue Cross and Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon. Elevance Health serves Individual, Employer Group, Medicaid, and Medicare markets, offering network-based managed care risk-based plans. It also provides fee-based managed care services such as claims processing, stop loss insurance, care provider network access, medical management, and actuarial services. The company administers the Federal Employee Program (FEP) for the U.S. federal government. Through its CarelonRx business, it offers pharmacy services, while Carelon Services provides integrated health services, including dental, vision, and supplemental health insurance benefits. Elevance Health is an independent licensee of the Blue Cross and Blue Shield Association (BCBSA), serving as the licensee for multiple states including California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia, and Wisconsin. The company is licensed to conduct insurance operations in all 50 states, the District of Columbia, and Puerto Rico.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Healthcare Plans Homepage elevancehealth.com
Sector Healthcare IR page ir.elevancehealth.com/investors/default.aspx
Tags
managed care, medicare advantage, medicaid, commercial health insurance, pharmacy benefits, behavioral health, stop loss insurance, federal employee health, dental and vision benefits, care management, Anthem Blue Cross, Anthem Blue Cross and Blue Shield, Wellpoint, Carelon, CarelonRx, Carelon Services, Federal Employee Program, FEP, Simply Healthcare, MMM
Press page elevancehealth.com/newsroom

Metrics

Valuation  
Market cap $ 95.09B
Market cap (USD) $ 95.09B
P/E 18.69
PEG —
P/BV 2.13
P/S 0.47
P/OCF 12.52
P/FCF 14.60
Dividend yield <0.01%
Turnover / mcap —
Returns  
ROE 13.3%
ROI 7.5%
ROIC 8.0%
Profit margin 2.8%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) -2.1%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 68.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 12
Quality score 42.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 199.125B 177.011B 171.34B 156.595B 138.639B 121.867B 104.213B 92.105B 90.039B 84.863B 79.157B 73.874B 71.024B 61.712B 60.711B 58.802B 65.028B 57.952B 61.134B 56.953B 45.136B 20.815B 16.771B 13.282B — —
Net profit 5.662B 5.98B 5.987B 6.025B 6.104B 4.572B 4.807B 3.75B 3.843B 2.47B 2.56B 2.57B 2.49B 2.656B 2.647B 2.887B 4.746B 2.491B 3.345B 3.095B 2.464B 960.1M 774.3M 549.1M — —
Free cash flow 3.174B 4.552B 6.765B 7.247B 7.277B 9.667B 4.984B 2.619B 3.385B 2.621B 3.478B 2.655B 2.406B 2.2B 2.855B 965.3M 2.661B 2.19B 4.023B 3.85B 3.095B 1.166B 1.033B 867.8M 584.2M 611.2M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 350.55 368.9 471.56 512.97 463.54 321.09 302.03 262.63 225.01 143.77 139.44 125.67 109.03 60.91 66.24 56.36 58.23 41.82 — — — — — — — —
Price performance 12m -0.05 -0.22 -0.08 0.11 0.44 0.06 0.15 0.17 0.57 0.03 0.11 0.15 0.79 -0.08 0.18 -0.03 0.39 — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) 1.37B 2.55B 1.99B 2.3B 700M 1.87B 1.77B 1.87B 2.01B 1.25B
Borrowings, non-current (USD) 14.4B 17.4B 17.2B 17.8B 19.3B 21.2B 22.3B 23.2B 29.2B 30.8B
Lease liabilities (USD) — — 728M — 957M 997M 932M 849M 811M 660M
Cash and deposits (USD) 4.08B 3.61B 3.93B 4.94B 5.74B 4.88B 7.39B 6.53B 8.29B 9.49B
Intangible assets (USD) 7.96B 8.37B 9.01B 8.67B 9.41B 10.6B 10.3B 10.3B 12.1B 11.2B
Right-of-use assets (USD) — — 637M — — 628M 604M 584M 567M 452M
Net debt (borrowings + leases - cash) (USD) 11.7B 16.3B 15.3B 15.1B 15.3B 19.1B 17.7B 19.4B 23.8B 23.2B
Cash flow detail
Operating cash flow (USD) 3.2B 4.18B 3.83B 6.06B 10.7B 8.36B 8.4B 8.06B 5.81B 4.29B
Purchases of property, plant and equipment (USD) -584M -800M -1.21B -1.08B -1.02B -1.09B -1.15B -1.3B -1.26B -1.12B
Change in receivables (cash effect) (USD) -1.38B -22.2M -695M -1.05B -256M -2.14B -2.51B -1.76B -683M -2.53B
Change in payables (cash effect) (USD) 117M 922M 122M -593M — — — — — —
Dividends paid (cash effect) (USD) -684M -705M -776M -818M -954M -1.1B -1.23B -1.4B -1.51B -1.53B
Share buybacks (cash effect) (USD) 0.00 -2B -1.69B -1.7B -2.7B -1.9B -2.32B -2.68B -2.9B -2.61B
Interest paid (cash effect) (USD) -595M -778M -728M -755M -794M -822M -878M -1.03B -1.24B -1.41B
Income taxes paid (cash effect) (USD) -1.67B -1.5B -738M -1.4B -1.79B -1.3B -1.59B -1.94B -1.3B -1.37B
Share-based compensation (USD) 165M 170M 226M 294M 283M 255M 264M 289M 191M 276M
Operating cash flow before change in receivables (USD) 4.59B 4.21B 4.52B 7.11B 10.9B 10.5B 10.9B 9.82B 6.49B 6.82B
Free cash flow (OCF - PPE - intangibles) (USD) 2.62B 3.39B 2.62B 4.98B 9.67B 7.28B 7.25B 6.77B 4.55B 3.17B
Income detail
Total comprehensive income (USD) 2.49B 4.01B 3.28B 5.5B 5.02B 5.78B 3.7B 7.16B 6.15B 6.36B
Comprehensive income to owners (USD) 2.49B 4.01B 3.28B 5.5B 5.02B 5.78B 3.7B 7.16B 6.15B 6.36B
Reported Feb 22, 2017 Feb 21, 2018 Apr 24, 2019 Feb 19, 2020 Feb 18, 2021 Oct 19, 2022 Feb 15, 2023 Feb 21, 2024 Feb 20, 2025 Feb 6, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Elevance Health, Inc. — Regulation FD Disclosure Bull 0 Bear 0 Guidance

Officers of Elevance Health, Inc. (the “Company”) expect to speak with investors and analysts this week. During these meetings, Company officers will reaffirm the Company’s shareholders’ earnings guidance for full year 2026 to be at least $22.00 per diluted share, including approximately $7.00 per diluted share of net unfavorable items. Excluding these items, the Company continues to expect adjusted shareholders’ earnings to be at least $29.00 per diluted share. This does not include any other adjustment items beyond those reported in the Company's third quarter 2026 earnings.

During these meetings, Company officers will also reaffirm full year 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points.

None of the information furnished in Item 7.01 hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

FORWARD-LOOKING STATEMENTS

Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts.

Press Release

October 21, 2026

Share on Linkedin Share on Facebook Share on X http://www.elevancehealth.com/newsroom/elv-quarterly-earnings-q3-2026

Share via Link

Indianapolis, IN- October 21, 2026 - Elevance Health, Inc. (NYSE: ELV) reported third quarter 2026 results ahead of expectations.

"Elevance Health's third quarter results reflect stronger execution across our diversified portfolio and underscore the earnings power of the business. We are raising our 2026 earnings outlook and remain confident in delivering at least 12% growth in adjusted diluted earnings per share in 2027 from our higher earnings baseline of at least $26.75*** . By bringing together the capabilities of our Health Benefits business and Carelon, we are improving the healthcare experience, strengthening our competitive advantage, and creating long-term value for our shareholders."

Gail K. Boudreaux President and Chief Executive Officer

  • Earnings per diluted share ("EPS"). ** Refer to GAAP reconciliation tables. *** FY 2026 earnings baseline excludes non-recurring net investment income and other non-operating items, as well as targeted one-time investments

Consolidated Enterprise Highlights

Operating revenue was $50.4 billion in the third quarter of 2026, an increase of $0.4 billion compared to the prior year quarter. This was driven by higher premium yields, increased CarelonRx product revenue, and growth in service fees, partially offset by lower Medicare Advantage, Medicaid, and Employer Group risk membership.

The benefit expense ratio of 90.6 percent improved 70 basis points, driven by better performance in Medicare Advantage and Individual ACA compared to the prior year.

Days in Claims Payable stood at 44.9 days as of September 30, 2026, an increase of 3.5 days year over year.

The operating expense ratio was 11.4 percent. The adjusted operating expense ratio was 11.3 percent, an increase of 90 basis points from the prior year. The increase principally reflected targeted, one-time investments in capabilities that support our long-term performance, along with spending to advance business growth and quality initiatives.

Cash Flow & Balance Sheet

Operating cash flow of $1.3 billion in the quarter increased $0.1 billion relative to the prior year, primarily reflecting favorable working capital dynamics. As of September 30, 2026, cash and investments at the parent company totaled approximately $2.4 billion.

During the third quarter of 2026, the Company repurchased 0.8 million shares of its common stock for $330 million, at a weighted average price of $398.75 per share, and paid a quarterly dividend of $1.72 per share, representing a distribution of cash totaling $373 million. As of September 30, 2026, the Company had approximately $5.0 billion of Board approved share repurchase authorization remaining.

Reportable Segment Highlights

Health Benefits is comprised of Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid, and Federal Employee Program businesses.

Health Benefits segment operating revenue was $43.4 billion in the third quarter of 2026, an increase of $1.1 billion, or 3 percent compared to the prior year quarter, driven primarily by higher premium yields and service fee revenue, partially offset by lower Medicare Advantage, Medicaid, and Employer Group risk membership.

Operating gain was $0.4 billion, a decline year over year, reflecting the impact of targeted investments to support our long-term operating model. This was partially offset by the improvement in our benefit expense ratio.

Medical membership of approximately 44.9 million as of September 30, 2026 decreased by 487 thousand compared to the prior year. The decline reflected lower enrollment in our Medicaid, Medicare Advantage, and Employer Group risk-based businesses, partially offset by growth in Commercial feebased membership

Carelon is comprised of CarelonRx and Carelon Services.

Operating revenue for Carelon was $19.3 billion in the third quarter of 2026, an increase of $1.0 billion, or 5 percent compared to the prior year quarter. Growth was driven by CarelonRx product revenue and continued expansion of Carelon Services risk-based solutions.

Operating gain for Carelon totaled $0.9 billion, an increase of 17 percent year over year, reflecting strong performance of Carelon Services risk-based solutions and the improved profitability of our specialty pharmacy.

Quarterly Dividend

On October 20, 2026, the Audit Committee of the Company's Board of Directors declared a fourth quarter 2026 dividend to shareholders of $1.72 per share. The fourth quarter dividend is payable on December 18, 2026 to shareholders of record at the close of business on December 4, 2026.

About Elevance Health

Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey – connecting them to the care, support, and resources they need to lead better lives. Elevance Health’s companies serve approximately 103 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, home health, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.

Conference Call and Webcast

Management will host a conference call and webcast today at 8:30 a.m. Eastern Daylight Time (“EDT”) to discuss the company’s second quarter results and outlook. The conference call should be accessed at least 15 minutes prior to the start of the call with the following numbers:

  • 888-947-9963 (Domestic)

  • 800-391-9853 (Domestic Replay)

  • 312-470-0178 (International)

  • 203-369-3269 (International Replay)

The access code for today's conference call is 3972058. There is no access code for the replay. The replay will be available from 11:30 a.m. EDT today, until the end of the day on November 20, 2026. The call will also be available through a live webcast at www.elevancehealth.com under the “Investors” link. A webcast replay will be available following the call.

Basis of Presentation

  1. Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reporting segments, allocate resources, set incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible assets, gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of operating segment management. Refer to the GAAP reconciliation tables.

  2. Operating margin is defined as operating gain divided by operating revenue.

Elevance Health Contacts

Investor Relations: Nathan Rich [email protected]

Media Contact: Leslie Porras [email protected]

Forward-Looking Statements

This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan,” "potential," "predict" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or regulations, including any investigations, claims or litigation related thereto; failure to effectively maintain and modernize our information systems, or failure of our information systems or technology, including artificial intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star Ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated with providing healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; the effects of any negative publicity or sentiment related to the health benefits industry in general or us in particular; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.

Feedback

Press Release

October 5, 2026

http://www.elevancehealth.com/newsroom/elevance-health-to-hold-conference-call-to-discuss-q3-2026-results

INDIANAPOLIS, IN – October 5, 2026 – Elevance Health (NYSE: ELV) will release third quarter 2026 financial results on October 21, 2026 at 6:00 a.m. Eastern Daylight Time (“EDT”). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers:

  • 888-947-9963 - Access Code - 3972058 (Domestic)

  • 312-470-0178 - Access Code - 3972058 (International)

  • 800-391-9853 - No Access Code (Domestic Replay)

  • 203-369-3269 - No Access Code (International Replay)

The call will be available through a live webcast at www.elevancehealth.com

 under the “Investors” link. You may also access the webcast here

. A webcast replay will be available from 11:30 a.m. EDT on October 21, 2026, until the end of the day on November 20, 2026.

Prompts

Elevance Health, Inc. (ticker ELV), listed in United States.

Company History

Date Change Detail
Jun 28, 2022 Renamed ANTHEM, INC. → ELEVANCE HEALTH, INC.
Dec 2, 2014 Renamed WELLPOINT, INC → ANTHEM, INC.
Nov 30, 2004 Renamed ANTHEM INC → WELLPOINT INC

ETFs Holding Elevance Health, Inc.

ETF Weight in ETF Shares Market value As of
DIVE 4.81% 5,390 $ 2.405M Nov 17, 2026
CAMX 4.42% 8,000 $ 3.007M Jul 31, 2026
BEEX 3.94% 16,488 $ 7.358M Nov 17, 2026
GFGF 3.64% 3,065 $ 1.203M Aug 31, 2026
CVGD 3.56% 13,113 $ 4.928M Jul 31, 2026
PJFM 3.47% 1,588 $ 689.081K Nov 18, 2026
BASV 2.26% 23,821 $ 9.212M Jun 30, 2026
CSTK 2.20% 10,291 $ 3.868M Jul 31, 2026
JHAC 2.10% 192 $ 74.252K Jun 30, 2026
ABCS 2.08% 661 $ 259.469K Aug 31, 2026
QVAL 2.04% 34,273 $ 14.87M Nov 18, 2026
BAFE 1.99% 86,858 $ 33.591M Jun 30, 2026
FDIV 1.95% 3,050 $ 1.146M Jul 31, 2026
ECML 1.85% 5,108 $ 2.22M Nov 18, 2026
FEGE 1.80% 115,249 $ 45.24M Aug 31, 2026
TOLL 1.72% 2,564 $ 1.006M Aug 31, 2026
BKDV 1.65% 80,785 $ 30.362M Jul 31, 2026
EAGL 1.58% 173,863 $ 67.238M Jun 30, 2026
QLTY 1.45% 191,162 $ 75.039M Aug 31, 2026
DVAL 1.40% 2,618 $ 1.012M Jun 30, 2026
CLCV 1.33% 604 $ 227.007K Jul 31, 2026
TVAL 1.27% 32,537 $ 14.521M Nov 17, 2026
AVIE 1.27% 475 $ 211.983K Nov 16, 2026
GMOV 1.21% 3,313 $ 1.3M Aug 31, 2026
PY 1.04% 5,907 $ 2.284M Jun 30, 2026
SYLD 0.92% 24,249 $ 9.114M Jul 31, 2026
PINK 0.90% 6,911 $ 2.999M Nov 17, 2026
TMED 0.77% 456 $ 176.349K Jun 30, 2026
MFSV 0.73% 11,119 $ 4.365M Aug 31, 2026
LSEQ 0.70% 290 $ 124.61K Nov 13, 2026
FBCV 0.68% 3,202 $ 1.203M Jul 31, 2026
COPY 0.67% 7,192 $ 2.823M Aug 31, 2026
BDVL 0.64% 25,361 $ 11.318M Nov 16, 2026
BLCR 0.62% 135,614 $ 60.522M Nov 16, 2026
RDVI 0.60% 54,801 $ 23.536M Nov 11, 2026
VFVA 0.59% 14,426 $ 5.663M Aug 31, 2026
GOP 0.57% 1,120 $ 499.834K Nov 17, 2026
FLDZ 0.51% 54 $ 20.883K Jun 30, 2026
WCEO 0.48% 127 $ 47.732K Jul 31, 2026
LSVD 0.43% 7,404 $ 2.783M Jul 31, 2026
DFUV 0.42% 153,402 $ 65.948M Nov 12, 2026
JAVA 0.42% 72,703 $ 31.548M Nov 17, 2026
FELV 0.42% 34,592 $ 13.378M Jun 30, 2026
CAPE 0.39% 2,405 $ 930.086K Jun 30, 2026
LCTU 0.39% 9,864 $ 4.402M Nov 16, 2026
RGLO 0.38% 3,330 $ 1.288M Jun 30, 2026
GSPY 0.36% 5,518 $ 2.463M Nov 17, 2026
FHEQ 0.35% 8,603 $ 3.233M Jul 31, 2026
DFLV 0.33% 59,019 $ 25.372M Nov 12, 2026
IALT 0.30% 53,339 $ 23.804M Nov 16, 2026
ACIO 0.29% 18,049 $ 6.784M Jul 31, 2026
ADME 0.28% 2,222 $ 835.116K Jul 31, 2026
FEAC 0.28% 184 $ 71.158K Jun 30, 2026
CDX 0.26% 1,473.9314 $ 639.583K Nov 17, 2026
TACU 0.26% 105 $ 46.859K Nov 17, 2026
SGLC 0.25% 1,360 $ 533.854K Aug 31, 2026
AVLV 0.24% 122,339 $ 54.597M Nov 16, 2026
AVSU 0.24% 2,576 $ 1.15M Nov 16, 2026
HBTA 0.23% 1,477 $ 579.782K Aug 31, 2026
AFLG 0.23% 4,810 $ 2.147M Nov 16, 2026
XMAG 0.22% 1,121 $ 481.918K Nov 13, 2026
FYEE 0.21% 1,194 $ 448.753K Jul 31, 2026
EBI 0.20% 3,550 $ 1.394M Aug 31, 2026
ENHU 0.19% 40 $ 17.851K Nov 16, 2026
DFSU 0.18% 10,049 $ 4.32M Nov 12, 2026
AVUS 0.18% 57,248 $ 25.549M Nov 16, 2026
AVLC 0.18% 6,475 $ 2.89M Nov 16, 2026
AAUS 0.18% 2,058 $ 890K Nov 18, 2026
MODL 0.18% 4,749 $ 1.837M Jun 30, 2026
INRO 0.17% 2,231 $ 995.651K Nov 16, 2026
LGDX 0.17% 528 $ 235.636K Nov 17, 2026
GVLU 0.16% 966 $ 431.106K Nov 17, 2026
THRO 0.15% 35,370 $ 15.785M Nov 16, 2026
IQSZ 0.15% 674 $ 253.316K Jul 31, 2026
DCOR 0.14% 143,002 $ 61.477M Nov 12, 2026
ACVF 0.14% 548 $ 205.96K Jul 31, 2026
DFUS 0.13% 67,870 $ 29.177M Nov 12, 2026
DFAC 0.13% 259,776 $ 111.678M Nov 12, 2026
APUE 0.12% 7,658 $ 3.006M Aug 31, 2026
NTSD 0.12% 109 $ 42.154K Jun 30, 2026
VOXP 0.12% 18 $ 6,765.12 Jul 31, 2026
NTSX 0.12% 4,060 $ 1.57M Jun 30, 2026
ACVU 0.11% 720 $ 0.00 Nov 18, 2026
GDE 0.11% 1,358 $ 533.069K Aug 31, 2026
SFGV 0.11% 2,899 $ 1.26M Nov 18, 2026
DFAU 0.11% 32,434 $ 13.943M Nov 12, 2026
HCMT 0.10% 1,508 $ 566.767K Jul 31, 2026
FELC 0.08% 17,116 $ 6.619M Jun 30, 2026
MSLC 0.08% 8,574 $ 3.366M Aug 31, 2026
GEW 0.08% 313 $ 122.865K Aug 31, 2026
FLSP 0.08% 1,840 $ 711.583K Jun 30, 2026
THEQ 0.06% 52 $ 23.207K Nov 17, 2026
DFVX 0.05% 720 $ 309.528K Nov 12, 2026
CSHP 0.05% 448 $ 199.933K Nov 16, 2026
VSLU 0.05% 677 $ 261.816K Jun 30, 2026
DXUV 0.05% 6,822 $ 2.933M Nov 12, 2026
DYNF 0.01% 13,740 $ 6.132M Nov 16, 2026
FMDE 0.00% 9 $ 3,480.57 Jun 30, 2026
CORO 0.00% 137 $ 61.04K Nov 16, 2026
NTRL short 0.00% -175 $ 0.00 Nov 16, 2026